Loxx 30/Loxx 60 Warnings

Symptoms associated with discontinuation of Duloxetine (Loxx 30/Loxx 60) Delayed Release Capsules and other selective serotonin reuptake inhibitors (SSRIs) and SSNRIs have been reported. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. At least 14 days should elapse between discontinuation of a MAOI and initiation of therapy with Duloxetine (Loxx 30/Loxx 60) Delayed Release Capsules. In addition, at least 5 days should be allowed after stopping Duloxetine Delayed Release Capsules before starting MAOI. All patients being treated with antidepressants like Duloxetine (Loxx 30/Loxx 60) delayed-release capsule for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.
Duloxetine (Loxx 30/Loxx 60) Delayed Release Capsules should be discontinued in patients who develop jaundice or other evidence of clinically significant liver dysfunction, symptomatic orthostatic hypotension and/or syncope, symptomatic hyponatremia, or urinary hesitancy and retention. Blood pressure should be measured prior to initiating treatment and periodically measured throughout the duration for which Duloxetine (Loxx 30/Loxx 60) Delayed Release Capsules is taken.
Treatment with Duloxetine (Loxx 30/Loxx 60) Delayed Release Capsules and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately serotonin syndrome or NMS-like reactions occur and supportive symptomatic treatment should be initiated.
Duloxetine (Loxx 30/Loxx 60) Delayed Release Capsules should ordinarily not be prescribed to patients with substantial alcohol use. Smoking can reduce bioavailability of Duloxetine (Loxx 30/Loxx 60) Delayed Release Capsules by about one-third. It should be advocated with due precaution along with aspirin, NSAIDs, warfarin and other anti-coagulants.